Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622520 | 1.00 | HDAC1 (0.41) | HDAC1HDAC2CDK1TSHRHTT | |
| SCHEMBL612139 | 1.00 | HDAC1 (0.41) | HDAC1HDAC2CDK1TSHRHTT | |
| SCHEMBL611975 | 0.96 | HDAC1 (0.45) | HDAC1HDAC2CDK1TSHRHTT | |
| SCHEMBL611974 | 0.96 | HDAC1 (0.45) | HDAC1HDAC2CDK1TSHRHTT | |
| SCHEMBL608240 | 0.92 | CDK1 (0.41) | HDAC1HDAC2CDK1ALDH1A1KDM4E | |
| SCHEMBL608239 | 0.92 | CDK1 (0.41) | HDAC1HDAC2CDK1ALDH1A1KDM4E | |
| SCHEMBL13622524 | 0.92 | CDK1 (0.41) | HDAC1HDAC2CDK1ALDH1A1KDM4E | |
| SCHEMBL612362 | 0.90 | ADORA2A (0.47) | HDAC1HDAC2TSHRHTTALDH1A1 | |
| SCHEMBL612363 | 0.90 | ADORA2A (0.47) | HDAC1HDAC2TSHRHTTALDH1A1 | |
| SCHEMBL16203696 | 0.84 | HDAC1 (0.56) | HDAC1HDAC2CDK1TMIGD3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268607-B9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-05-13 | — | — | EP | disclosed |
| EP-2268607-B1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-02-18 | — | — | EP | disclosed |
| EP-2268607-B1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-02-18 | — | — | EP | disclosed |
| US-8895734-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8884008-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-11 | — | — | US | disclosed |
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-10-30 | — | — | US | disclosed |
| US-8859766-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-10-14 | — | — | US | disclosed |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2014-06-05 | — | — | US | disclosed |
| US-8680253-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-03-25 | — | — | US | disclosed |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2012-02-16 | — | — | US | disclosed |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323728-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | HDAC1 4236/4885HDAC2 4426/4885CDK1 3785/4885 |
| US-20140155605-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | HDAC1 4236/4885HDAC2 4426/4885CDK1 3785/4885 |
| US-20120040918-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | HDAC1 4236/4885HDAC2 4426/4885CDK1 3785/4885 |
| US-20110178031-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | HDAC1 4236/4885HDAC2 4426/4885CDK1 3785/4885 |
| US-20140155604-A1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | SLC7A1, SLC29A1, SLC43A3 | HDAC1 4236/4885HDAC2 4426/4885CDK1 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.